肠道菌群在高血压治疗中的研究进展

doi:10.3969/j.issn.1006-5725.2025.19.025

Abstract

Abstract:

Hypertension is an important risk factor that causes cardiovascular diseases and premature death in China. The pathogenesis of hypertension is complex and affected by numerous factors. Gut microbiota are involved in regulating many physiological processes of human body， making it a key factor in human health. Many studies have shown that there are close relationships between gut microbiota dysbiosis and the onset and progression of hypertension. Restoring gut microbiota homeostasis can reduce blood pressure. Thus， gut microbiota has become a potential therapeutic target for hypertension. Therefore， this article mainly reviews the connection between gut microbiota and hypertension， as well as the study progress of adjusting gut microbiota homeostasis for the prevention and treatment of hypertension.

Key words: gut microbiota, hypertension, fecal microbiota transplantation

CLC Number:

R544.1

Yilin HUANG,Shuang LI,Zhengyong HE,Zeyu. ZHANG. Research progress on fecal microbiota transplantation for the treatment of hypertension[J]. The Journal of Practical Medicine, 2025, 41(19): 3129-3134.

References 55

[1]	赵冬. 中国成人高血压流行病学现状［J］. 中国心血管杂志， 2020， 25（6）： 513-515.
[2]	曲凤霞，李婧媛，郭晓，等. 互联网+心脏康复对高血压合并冠心病患者干预的疗效［J］. 实用医学杂志， 2024， 40（19）： 2778-2782.
[3]	WANG Z， CHEN Z， ZHANG L， et al. Status of Hypertension in China： Results From the China Hypertension Survey， 2012-2015 ［J］. Circulation， 2018， 137（22）： 2344-2356. doi:10.1161/circulationaha.117.032380 doi: 10.1161/circulationaha.117.032380
[4]	国家心血管病中心，中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2023概要［J］. 中国循环杂志， 2024， 39（7）： 625-660.
[5]	李立明，饶克勤，孔灵芝，等. 中国居民营养与健康状况调查技术执行组. 中国居民2002年营养与健康状况调查［J］. 中华流行病学杂志， 2005， 26（7）： 478-84.
[6]	MA J， CHEN X. Advances in pathogenesis and treatment of essential hypertension ［J］. Front Cardiovasc Med， 2022， 9： 1003852. doi:10.3389/fcvm.2022.1003852 doi: 10.3389/fcvm.2022.1003852
[7]	LI Y， DENG Q， LIU Z. The relationship between gut microbiota and insomnia： A bi-directional two-sample Mendelian randomization research ［J］. Front Cell Infect Microbiol， 2023， 13： 1296417. doi:10.3389/fcimb.2023.1296417 doi: 10.3389/fcimb.2023.1296417
[8]	LI J， ZHAO F， WANG Y， et al. Gut microbiota dysbiosis contributes to the development of hypertension ［J］. Microbiome， 2017， 5（1）： 14. doi:10.1186/s40168-016-0222-x doi: 10.1186/s40168-016-0222-x
[9]	毕馨文，崔远捷，陆秋娴，等. 肠道菌群对高脂饮食诱导肥胖小鼠糖脂代谢紊乱的免疫调节作用［J］. 实用医学杂志， 2024， 40（11）： 1505-1512.
[10]	YANG T， MAKI K A， MARQUES F Z， et al. Hypertension and the Gut Microbiome： A Science Advisory From the American Heart Association ［J］. Hypertension， 2025，82（9）：e160-e170. doi:10.1161/hyp.0000000000000247 doi: 10.1161/hyp.0000000000000247
[11]	SHI H， ZHANG B， ABO-HAMZY T， et al. Restructuring the Gut Microbiota by Intermittent Fasting Lowers Blood Pressure ［J］. Circ Res， 2021， 128（9）： 1240-1254. doi:10.1161/circresaha.120.318155 doi: 10.1161/circresaha.120.318155
[12]	PAPAKONSTANTINOU E， ZACHARODIMOS N， GEORGIOPOULOS G， et al. Two-Month Consumption of Orange Juice Enriched with Vitamin D3 and Probiotics Decreases Body Weight， Insulin Resistance， Blood Lipids， and Arterial Blood Pressure in High-Cardiometabolic-Risk Patients on a Westernized Type Diet： Results from a Randomized Clinical Trial ［J］. Nutrients， 2024， 16（9）： 1331. doi:10.3390/nu16091331 doi: 10.3390/nu16091331
[13]	LI K， JIANG P， LI S， et al. ACE inhibitory casein peptide lowers blood pressure and reshapes gut microbiota in a randomized double blind placebo controlled trial ［J］. Sci Rep， 2025， 15（1）： 13840. doi:10.1038/s41598-025-98446-6 doi: 10.1038/s41598-025-98446-6
[14]	PALMU J， SALOSENSAARI A， HAVULINNA A S， et al. Association Between the Gut Microbiota and Blood Pressure in a Population Cohort of 6953 Individuals ［J］. J Am Heart Assoc， 2020， 9（15）： e016641. doi:10.1161/jaha.120.016641 doi: 10.1161/jaha.120.016641
[15]	NAKAI M， RIBEIRO R V， STEVENS B R， et al. Essential Hypertension Is Associated With Changes in Gut Microbial Metabolic Pathways： A Multisite Analysis of Ambulatory Blood Pressure ［J］. Hypertension， 2021， 78（3）： 804-815. doi:10.1161/hypertensionaha.121.17288 doi: 10.1161/hypertensionaha.121.17288
[16]	MUSHTAQ N， HUSSAIN S， ZHANG S， et al. Molecular characterization of alterations in the intestinal microbiota of patients with grade 3 hypertension ［J］. Int J Mol Med， 2019， 44（2）： 513-522.
[17]	DINAKIS E， NAKAI M， GILL P， et al. Association Between the Gut Microbiome and Their Metabolites With Human Blood Pressure Variability ［J］. Hypertension， 2022， 79（8）： 1690-1701. doi:10.1161/hypertensionaha.122.19350 doi: 10.1161/hypertensionaha.122.19350
[18]	FANG C， ZUO K， FU Y， et al. Aggravated Gut Microbiota and Metabolomic Imbalances Are Associated with Hypertension Patients Comorbid with Atrial Fibrillation ［J］. Biomolecules， 2022， 12（10）：1445. doi:10.3390/biom12101445 doi: 10.3390/biom12101445
[19]	LIN Y T， SAYOLS-BAIXERAS S， BALDANZI G， et al. The association between the gut microbiome and 24-h blood pressure measurements in the SCAPIS study ［J］. Commun Med， 2025， 5（1）： 276. doi:10.1038/s43856-025-00980-x doi: 10.1038/s43856-025-00980-x
[20]	XIONG Y， HE Y， CHEN Z， et al. Lactobacillus induced by irbesartan on spontaneously hypertensive rat contribute to its antihypertensive effect ［J］. J Hypertens， 2024， 42（3）： 460-470. doi:10.1097/hjh.0000000000003613 doi: 10.1097/hjh.0000000000003613
[21]	YUN F， HAN X， WANG Z， et al. Intermittent fasting ameliorates resistant hypertension through modulation of gut microbiota ［J］. Pharmacol Res， 2025： 107864. doi:10.1016/j.phrs.2025.107864 doi: 10.1016/j.phrs.2025.107864
[22]	XU X， JIN H， LI X， et al. Fecal Microbiota Transplantation Regulates Blood Pressure by Altering Gut Microbiota Composition and Intestinal Mucosal Barrier Function in Spontaneously Hypertensive Rats ［J］. Probiotics Antimicrob Proteins， 2024， 219：107864. doi:10.1007/s12602-024-10344-x doi: 10.1007/s12602-024-10344-x
[23]	GUO J， JIA P， GU Z， et al. Altered gut microbiota and metabolite profiles provide clues in understanding resistant hypertension ［J］. J Hypertens， 2024， 42（7）： 1212-1225. doi:10.1097/hjh.0000000000003716 doi: 10.1097/hjh.0000000000003716
[24]	PLUZNICK J L. Microbial Short-Chain Fatty Acids and Blood Pressure Regulation ［J］. Curr Hypertens Rep， 2017， 19（4）： 25. doi:10.1007/s11906-017-0722-5 doi: 10.1007/s11906-017-0722-5
[25]	SAM Q H， LING H， YEW W S， et al. The Divergent Immunomodulatory Effects of Short Chain Fatty Acids and Medium Chain Fatty Acids ［J］. Int J Mol Sci， 2021， 22（12）： 6453. doi:10.3390/ijms22126453 doi: 10.3390/ijms22126453
[26]	TANG W H W， WANG Z， LEVISON B S， et al. Intestinal Microbial Metabolism of Phosphatidylcholine and Cardiovascular Risk ［J］. N Engl J Med， 2013， 368（17）： 1575-1584. doi:10.1056/nejmoa1109400 doi: 10.1056/nejmoa1109400
[27]	JIANG S， SHUI Y， CUI Y， et al. Gut microbiota dependent trimethylamine N-oxide aggravates angiotensin Ⅱ-induced hypertension ［J］. Redox Biol， 2021， 46： 102115. doi:10.1016/j.redox.2021.102115 doi: 10.1016/j.redox.2021.102115
[28]	LI W， LIANG P， MA X， et al. The Association Between High-Sensitivity C-Reactive Protein and the Progression of Arteriosclerosis： The Kailuan Study ［J］. J Inflamm Res， 2025， 18： 7047-7054. doi:10.2147/jir.s524495 doi: 10.2147/jir.s524495
[29]	MUKOHDA M， YANO T， MATSUI T， et al. Treatment with Ligilactobacillus murinus lowers blood pressure and intestinal permeability in spontaneously hypertensive rats ［J］. Sci Rep， 2023， 13（1）： 15197. doi:10.1038/s41598-023-42377-7 doi: 10.1038/s41598-023-42377-7
[30]	EISEMAN B， SILEN W， BASCOM G S， et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis ［J］. Surgery， 1958， 44（5）： 854-859.
[31]	TORAL M， ROBLES-VERA I， DE LA VISITACIÓN N， et al. Critical Role of the Interaction Gut Microbiota-Sympathetic Nervous System in the Regulation of Blood Pressure ［J］. Front Physiol， 2019， 10： 231. doi:10.3389/fphys.2019.00231 doi: 10.3389/fphys.2019.00231
[32]	XIA W J， XU M L， YU X J， et al. Antihypertensive effects of exercise involve reshaping of gut microbiota and improvement of gut-brain axis in spontaneously hypertensive rat ［J］. Gut Microbes， 2021， 13（1）： 1-24. doi:10.1080/19490976.2020.1854642 doi: 10.1080/19490976.2020.1854642
[33]	MARQUES F Z， NELSON E， CHU P Y， et al. High-Fiber Diet and Acetate Supplementation Change the Gut Microbiota and Prevent the Development of Hypertension and Heart Failure in Hypertensive Mice ［J］. Circulation， 2017， 135（10）： 964-977. doi:10.1161/circulationaha.116.024545 doi: 10.1161/circulationaha.116.024545
[34]	ZHONG H J， ZENG H L， CAI Y L， et al. Washed Microbiota Transplantation Lowers Blood Pressure in Patients With Hypertension ［J］. Front Cell Infect Microbiol， 2021， 11： 679624. doi:10.3389/fcimb.2021.679624 doi: 10.3389/fcimb.2021.679624
[35]	FAN L， CHEN J， ZHANG Q， et al. Fecal microbiota transplantation for hypertension： An exploratory， multicenter， randomized， blinded， placebo-controlled trial ［J］. Microbiome， 2025， 13（1）： 133. doi:10.1186/s40168-025-02118-6 doi: 10.1186/s40168-025-02118-6
[36]	ZHANG Y， ZHENG T， MA D， et al. Probiotics Bifidobacterium lactis M8 and Lactobacillus rhamnosus M9 prevent high blood pressure via modulating the gut microbiota composition and host metabolic products ［J］. mSystems， 2023， 8（6）： e0033123. doi:10.1128/msystems.00331-23 doi: 10.1128/msystems.00331-23
[37]	ZHOU T， WANG Z， LV X， et al. Targeting gut S. aureofaciens Tü117 serves as a new potential therapeutic intervention for the prevention and treatment of hypertension ［J］. Cell Metab， 2025， 37（2）： 496-513.e11. doi:10.1016/j.cmet.2025.01.004 doi: 10.1016/j.cmet.2025.01.004
[38]	MAIA L A， DE SOUZA J R， SILVA L F R DA， et al. Effects of Probiotics on Inflammatory Biomarkers and Its Associations With Cardiac Autonomic Function in Women With Arterial Hypertension： A Secondary Analysis of a Randomized Clinical Trial ［J］. Probiotics Antimicrob Proteins， 2025， 17（4）： 1921-1928. doi:10.1007/s12602-024-10303-6 doi: 10.1007/s12602-024-10303-6
[39]	ZHENG L， ZHANG J， YANG J， et al. Association of the use of nonfood prebiotics， probiotics， and synbiotics with total and cause-specific mortality： a prospective cohort study ［J］. Nutr J， 2025， 24（1）： 45. doi:10.1186/s12937-025-01104-w doi: 10.1186/s12937-025-01104-w
[40]	JAUHIAINEN T， VAPAATALO H， POUSSA T， et al. Lactobacillus helveticus fermented milk lowers blood pressure in hypertensive subjects in 24-h ambulatory blood pressure measurement ［J］. Am J Hypertens， 2005， 18（12 Pt 1）： 1600-1605. doi:10.1016/j.amjhyper.2005.06.006 doi: 10.1016/j.amjhyper.2005.06.006
[41]	TALADRID D， DE CELIS M， BELDA I， et al. Hypertension- and glycaemia-lowering effects of a grape-pomace-derived seasoning in high-cardiovascular risk and healthy subjects. Interplay with the gut microbiome ［J］. Food Funct， 2022， 13（4）： 2068-2082. doi:10.1039/d1fo03942c doi: 10.1039/d1fo03942c
[42]	LI J， CHEN C， YANG H， et al. Tea polyphenols regulate gut microbiota dysbiosis induced by antibiotic in mice ［J］. Food Res Int， 2021， 141： 110153. doi:10.1016/j.foodres.2021.110153 doi: 10.1016/j.foodres.2021.110153
[43]	KIRSCHNER S K， ENGELEN M P K J， HAAS P， et al. Short-chain fatty acid kinetics and concentrations are higher after inulin supplementation in young and older adults： A randomized trial ［J］. Am J Clin Nutr， 2025， 121（6）： 1224-1235. doi:10.1016/j.ajcnut.2025.04.018 doi: 10.1016/j.ajcnut.2025.04.018
[44]	XUE Y， CUI L， QI J， et al. The effect of dietary fiber （oat bran） supplement on blood pressure in patients with essential hypertension： A randomized controlled trial ［J］. Nutr Metab Cardiovasc Dis， 2021， 31（8）： 2458-2470. doi:10.1016/j.numecd.2021.04.013 doi: 10.1016/j.numecd.2021.04.013
[45]	JAMA H A， RHYS-JONES D， NAKAI M， et al. Prebiotic intervention with HAMSAB in untreated essential hypertensive patients assessed in a phase II randomized trial ［J］. Nat Cardiovasc Res， 2023， 2（1）： 35-43. doi:10.1038/s44161-022-00197-4 doi: 10.1038/s44161-022-00197-4
[46]	FILIPPOU C， THOMOPOULOS C， KONSTANTINIDIS D， et al. DASH vs. Mediterranean diet on a salt restriction background in adults with high normal blood pressure or grade 1 hypertension： A randomized controlled trial ［J］. Clin Nutr， 2023， 42（10）： 1807-1816. doi:10.1016/j.clnu.2023.08.011 doi: 10.1016/j.clnu.2023.08.011
[47]	RINOTT E， MEIR A Y， TSABAN G， et al. The effects of the Green-Mediterranean diet on cardiometabolic health are linked to gut microbiome modifications： A randomized controlled trial ［J］. Genome Med， 2022， 14（1）： 29. doi:10.1186/s13073-022-01015-z doi: 10.1186/s13073-022-01015-z
[48]	SACKS F M， SVETKEY L P， VOLLMER W M， et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension （DASH） diet. DASH-Sodium Collaborative Research Group ［J］. N Engl J Med， 2001， 344（1）： 3-10.
[49]	CHEN L， HE F J， DONG Y， et al. Modest Sodium Reduction Increases Circulating Short-Chain Fatty Acids in Untreated Hypertensives： A Randomized， Double-Blind， Placebo-Controlled Trial ［J］. Hypertension， 2020， 76（1）： 73-79. doi:10.1161/hypertensionaha.120.14800 doi: 10.1161/hypertensionaha.120.14800
[50]	MU L， YU P， XU H， et al. Effect of sodium reduction based on the DASH diet on blood pressure in hypertensive patients with type 2 diabetes ［J］. Nutr Hosp， 2022， 39（3）： 537-546.
[51]	PEPINE C J， THIEL A， KIM S， et al. Potential of Minocycline for Treatment of Resistant Hypertension ［J］. Am J Cardiol， 2021， 156： 147-149. doi:10.1016/j.amjcard.2021.07.004 doi: 10.1016/j.amjcard.2021.07.004
[52]	GALLA S， CHAKRABORTY S， CHENG X， et al. Disparate effects of antibiotics on hypertension ［J］. Physiol Genomics， 2018， 50（10）： 837-845. doi:10.1152/physiolgenomics.00073.2018 doi: 10.1152/physiolgenomics.00073.2018
[53]	YANG T， SANTISTEBAN M M， RODRIGUEZ V， et al. Gut dysbiosis is linked to hypertension ［J］. Hypertension， 2015， 65（6）： 1331-1340. doi:10.1161/hypertensionaha.115.05315 doi: 10.1161/hypertensionaha.115.05315
[54]	GALLA S， CHAKRABORTY S， CHENG X， et al. Exposure to Amoxicillin in Early Life Is Associated With Changes in Gut Microbiota and Reduction in Blood Pressure： Findings From a Study on Rat Dams and Offspring ［J］. J Am Heart Assoc， 2020， 9（2）： e014373. doi:10.1161/jaha.119.014373 doi: 10.1161/jaha.119.014373
[55]	LI X， BREJNROD A， THORSEN J， et al. Differential responses of the gut microbiome and resistome to antibiotic exposures in infants and adults ［J］. Nat Commun， 2023， 14（1）： 8526. doi:10.1038/s41467-023-44289-6 doi: 10.1038/s41467-023-44289-6

Research progress on fecal microbiota transplantation for the treatment of hypertension

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 55

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Haiyang LU,Weili ZHAO,Xiaoxia. HU. Gut microbiota modulates immune reconstitution in allogeneic hematopoietic stem cell transplantation [J]. The Journal of Practical Medicine, 2025, 41(5): 628-633.
[2]	Jinzhou JING,Zelin LI,Zhengyi LUO,Yuying. HU. Gut microbiota dysbiosis in adolescent socially isolated mice with cognitive impairment and identification of key pathogenic microbial communities [J]. The Journal of Practical Medicine, 2025, 41(19): 3000-3007.
[3]	Yunfen TIAN,Bin WANG,Fangxiang ZHANG. Multi-target regulation of short-chain fatty acids in sepsis [J]. The Journal of Practical Medicine, 2025, 41(13): 2105-2110.
[4]	Wenhua SHI,Yuqian CHEN,Yonghong ZHANG,Cong LI,Cui ZHAI,Ni YANG,Rui KE. A study of underlying mechanisms of artemisinin inhibiting glycolysis through HIF-1α/LDHA pathway to improve pulmonary vascular remodeling [J]. The Journal of Practical Medicine, 2025, 41(1): 15-22.
[5]	Yanhong NING,Yuanshan XU,Xiaohua LI,Shihua LI,Zhenhua YANG,Yunhua LIAO,Ling. PAN. An observational study on the treatment of chronic kidney disease stage 5 with resistant hypertension with sacubitril/valsartan [J]. The Journal of Practical Medicine, 2024, 40(4): 543-548.
[6]	Zihui TIE,Peikun HE,Yanyi LI,Qingrui DUAN,Kun NIE,Lijuan. WANG. Exploratory study on the relationship between brain structural network changes and gut microbiota in patients with mild cognitive impairment associated with Parkinson′s disease [J]. The Journal of Practical Medicine, 2024, 40(24): 3438-3445.
[7]	Fengxia QU,Yue XIN,Jingyuan LI,Xiao GUO,Changhong. LU. Evaluation of the efficacy of Internet+cardiac rehabilitation intervention in patients with hypertension and coronary heart disease [J]. The Journal of Practical Medicine, 2024, 40(19): 2778-2782.
[8]	Yao ZHANG,Yingxin HUO,Wei ZHAO,Rongjie TANG,Qiufang. LIAN. The relationship between blood uric acid levels and non⁃alcoholic fatty liver disease in patients with type H hypertension [J]. The Journal of Practical Medicine, 2024, 40(18): 2561-2565.
[9]	Yan WANG,Tiejun PAN,Zhenyu LIU,Jinbo SUN,Yu ZHOU,Chaosheng LI,Lei. GAO. Protective role of intestinal microbial network in hyperoxaluria⁃induced kidney impairment in rats [J]. The Journal of Practical Medicine, 2024, 40(13): 1771-1777.
[10]	Qingyuan XU,Weifeng YUAN,Mu CHEN,Xiaoneng. MO. Research on the diagnostic value of pulmonary artery diameter characteristics and combined TNF-α in patients with HIV associated pulmonary hypertension [J]. The Journal of Practical Medicine, 2024, 40(13): 1869-1874.
[11]	Yanqing MAO,Ya′nan WANG,Jie. LI. The clinical symptoms， quality of life and laboratory indexes of newly diagnosed chronic obstructive pulmonary disease with hypertension [J]. The Journal of Practical Medicine, 2024, 40(11): 1549-1553.
[12]	Xiaobin GUO,Ping LIU,Wenxia. YU. The association between the waist⁃to⁃height ratio and novel cerebral infarction in the elderly with hypertension [J]. The Journal of Practical Medicine, 2024, 40(11): 1592-1596.
[13]	ZHANG Yi, HUANG Fenfei, XU Xuyan.. Relationship between serum matrix metalloproteinase ⁃ 9 and metalloproteinase ⁃ 1 expression in patients with chronic obstructive pulmonary disease and their predictive value for pulmonary vascular remodeling [J]. The Journal of Practical Medicine, 2023, 39(7): 849-854.
[14]	DAI Shuang, FENG Yanhong.. Fully automated 3D ultrasound right ventricular quantitative software to evaluate right ventricular systolic function in patients with systemic lupus erythematosus [J]. The Journal of Practical Medicine, 2023, 39(5): 636-641.
[15]	LUO Zhi⁃ mei, LIU Hongyan, SUN Desheng.. Application of a pulmonary vascular gene knockdown animal model in pulmonary hypertension [J]. The Journal of Practical Medicine, 2023, 39(4): 404-409.